| Autor: |
Tony A. Shindano, Manix I. Masimango, Antoine S. Kishabongo |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Health Science Reports, Vol 7, Iss 3, Pp n/a-n/a (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2398-8835 |
| DOI: |
10.1002/hsr2.1960 |
| Popis: |
Abstract Background and Aims Treating Helicobacter pylori infections has become a major challenge due to increased antibiotic resistance. The aim of this study was to investigate the efficacy and tolerability of the main standard regimens recommended for H. pylori eradication in Bukavu, Eastern of the Democratic Republic of Congo. Methods The study enrolled patients with evidence of H. pylori infection in histological examination or serology testing combined with a positive fecal antigen test. As first‐line treatment, patients were randomized to either a 10‐days (OAC‐10) or a 14‐days (OAC‐14) regimen, employing a combination of omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily. In case of failure, a second line regimen was evaluated and included two others protocols: OAC‐10 regimen + levofloxacin 500 mg (OAC‐10+) and the bismuth‐based therapy (pantoprazole + bismuth salt + metronidazole + tetracycline) during 10 days. Our primary endpoint was H. pylori eradication and secondarily, the compliance and adverse effects were also evaluated. Results A total of 179 patients were enrolled. The eradication rate was 79.2% and 80.5% with the OAC‐10 and OAC‐14 regimen, respectively (p = 0.796). Adverse effects were significant higher in the OAC‐14 group than in the OAC‐10 group (36.5% vs. 57.8%; p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text